Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
FBIO Stock Forecast 2025-2026
$2.83
Current Price
$87.84M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to FBIO Price Targets
+500.7%
To High Target of $17.00
+279.9%
To Median Target of $10.75
+59.0%
To Low Target of $4.50
FBIO Price Momentum
+0.4%
1 Week Change
+8.4%
1 Month Change
+38.0%
1 Year Change
+39.4%
Year-to-Date Change
-32.6%
From 52W High of $4.20
+112.8%
From 52W Low of $1.33
📊 TOP ANALYST CALLS
Did FBIO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Fortress Biotech is one of their latest high-conviction picks.
Latest FBIO Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, FBIO has a bullish consensus with a median price target of $10.75 (ranging from $4.50 to $17.00). The overall analyst rating is N/A (N/A/10). Currently trading at $2.83, the median forecast implies a 279.9% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joseph Pantginis at HC Wainwright & Co., projecting a 500.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
FBIO Analyst Ratings
2
Buy
0
Hold
0
Sell
FBIO Price Target Range
Low
$4.50
Average
$10.75
High
$17.00
Current: $2.83
Latest FBIO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for FBIO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 21, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $17.00 |
| Mar 11, 2025 | Roth MKM | Jason Wittes | Buy | Reiterates | $16.00 |
| Nov 18, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $26.00 |
| Jul 19, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $24.00 |
| Jun 20, 2024 | Cantor Fitzgerald | Jennifer Kim | Overweight | Reiterates | $N/A |
| May 16, 2024 | Roth MKM | Jason Wittes | Buy | Reiterates | $10.00 |
| Mar 19, 2024 | Alliance Global Partners | Buy | Initiates | $5.00 | |
| Mar 15, 2024 | Roth MKM | Jason Wittes | Buy | Reinstates | $10.00 |
| Nov 29, 2023 | Roth MKM | Scott Henry | Buy | Maintains | $15.00 |
| Aug 15, 2023 | Cantor Fitzgerald | Jennifer Kim | Overweight | Reiterates | $5.00 |
| May 16, 2023 | Cantor Fitzgerald | Jennifer Kim | Overweight | Maintains | $5.00 |
| Apr 6, 2023 | Benchmark | Robert Wasserman | Speculative Buy | Reiterates | $5.00 |
| Aug 4, 2022 | Ladenburg Thalmann | Jeffrey Cohen | Buy | Initiates | $6.00 |
| Jul 14, 2022 | B. Riley Securities | Mayank Mamtani | Buy | Maintains | $6.00 |
| Apr 20, 2021 | Roth Capital | Buy | Maintains | $5.00 | |
| Oct 13, 2020 | Roth Capital | Buy | Maintains | $4.75 | |
| Oct 12, 2020 | HC Wainwright & Co. | Buy | Maintains | $10.00 | |
| Oct 2, 2020 | Benchmark | Buy | Initiates | $N/A | |
| Mar 13, 2020 | B. Riley Securities | Mayank Mamtani | Buy | Maintains | $6.00 |
| Mar 13, 2020 | B. Riley FBR | Buy | Maintains | $N/A |
Fortress Biotech Inc. (FBIO) Competitors
The following stocks are similar to Fortress Biotech based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Fortress Biotech Inc. (FBIO) Financial Data
Fortress Biotech Inc. has a market capitalization of $87.84M with a P/E ratio of -1.1x. The company generates $62.30M in trailing twelve-month revenue with a 6.4% profit margin.
Revenue growth is +20.5% quarter-over-quarter, while maintaining an operating margin of -38.6% and return on equity of -205.3%.
Valuation Metrics
Market Cap
$87.84M
Enterprise Value
$74.89M
P/E Ratio
-1.1x
PEG Ratio
0.0x
Price/Sales
1.4x
Growth & Margins
Revenue Growth (YoY)
+20.5%
Gross Margin
+67.4%
Operating Margin
-38.6%
Net Margin
+6.4%
EPS Growth
+20.5%
Financial Health
Cash/Price Ratio
+98.2%
Current Ratio
2.2x
Debt/Equity
104.8x
ROE
-205.3%
ROA
-34.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Fortress Biotech Inc. (FBIO) Business Model
About Fortress Biotech Inc.
What They Do
Develops and commercializes novel biopharmaceutical products.
Business Model
The company operates by acquiring, developing, and commercializing therapies through subsidiary companies and licensing agreements. This innovative partnership model allows Fortress Biotech to focus on early-stage drug candidates and bring treatments for rare diseases and serious health conditions to market.
Additional Information
Fortress Biotech aims to address unmet medical needs in the healthcare sector and plays a crucial role in advancing medical treatments and pharmaceutical innovation.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
101
CEO
Dr. Lindsay Allan Rosenwald M.D.
Country
United States
IPO Year
2011
Website
www.fortressbiotech.comFortress Biotech Inc. (FBIO) Latest News & Analysis
Latest News
Quick Summary
Fortress Biotech (FBIO) reported quarterly earnings of $0.11 per share, surpassing the Zacks Consensus Estimate of a $0.43 loss, and improved from a $0.76 loss per share a year prior.
Why It Matters
Fortress Biotech's earnings beat expectations, signaling potential profitability and growth, which can boost investor confidence and stock price.
Source: Zacks Investment Research
Market Sentiment:
Positive
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
23 days ago
Quick Summary
Fortress Biotech's Q3 2025 revenue rose 20.5% to $17.6 million. It received ~$28 million from Checkpoint Therapeutics' acquisition by Sun Pharma and may earn an additional $4.8 million plus royalties on UNLOXCYT™.
Why It Matters
Fortress Biotech's revenue growth and strategic acquisitions signal strong financial health and potential future earnings, enhancing shareholder value through royalties and product advancements.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Fortress Biotech, Inc. will hold its Q3 2025 earnings call on November 12, 2025, at 4:30 PM EST, featuring key executives and analysts from various research divisions.
Why It Matters
The upcoming earnings call for Fortress Biotech may provide insights into financial performance, strategic direction, and market expectations, influencing stock price and investor confidence.
Source: Seeking Alpha
Market Sentiment:
Neutral
Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
25 days ago
Quick Summary
For Q3 2025, net revenues reached $17.6 million, with Emrosi™ prescriptions up 146% from Q2. Emrosi generated $4.9 million in revenue. A conference call is scheduled for 4:30 p.m. ET today.
Why It Matters
Significant revenue growth and a sharp increase in prescriptions for Emrosi™ indicate strong market demand, potentially boosting investor confidence and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025
1 month ago
Quick Summary
The company will hold a conference call on November 12, 2025, at 4:30 p.m. ET to discuss its financial results and provide a corporate update.
Why It Matters
The conference call will reveal financial performance and strategic updates, influencing stock valuations and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
1 month ago
Quick Summary
Avenue Therapeutics will have its subsidiary Baergic Bio acquired by Axsome Therapeutics, which includes global rights to BAER-101, now AXS-17.
Why It Matters
Avenue Therapeutics' acquisition by Axsome Therapeutics adds valuable assets, like BAER-101, enhancing Axsome's pipeline and potential market position, influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About FBIO Stock
What is Fortress Biotech Inc.'s (FBIO) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Fortress Biotech Inc. (FBIO) has a median price target of $10.75. The highest price target is $17.00 and the lowest is $4.50.
Is FBIO stock a good investment in 2026?
According to current analyst ratings, FBIO has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.83. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for FBIO stock?
Wall Street analysts predict FBIO stock could reach $10.75 in the next 12 months. This represents a 279.9% increase from the current price of $2.83. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Fortress Biotech Inc.'s business model?
The company operates by acquiring, developing, and commercializing therapies through subsidiary companies and licensing agreements. This innovative partnership model allows Fortress Biotech to focus on early-stage drug candidates and bring treatments for rare diseases and serious health conditions to market.
What is the highest forecasted price for FBIO Fortress Biotech Inc.?
The highest price target for FBIO is $17.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 500.7% increase from the current price of $2.83.
What is the lowest forecasted price for FBIO Fortress Biotech Inc.?
The lowest price target for FBIO is $4.50 from at , which represents a 59.0% increase from the current price of $2.83.
What is the overall FBIO consensus from analysts for Fortress Biotech Inc.?
The overall analyst consensus for FBIO is bullish. Out of 8 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $10.75.
How accurate are FBIO stock price projections?
Stock price projections, including those for Fortress Biotech Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 4:02 PM UTC